Abstract: Provided herein are novel sugar derivatives which are intermediates for preparing senolytic agents that selectively kill senescent cells associated with numerous pathologies and diseases, including age-related pathologies and diseases.
Type:
Grant
Filed:
September 13, 2022
Date of Patent:
February 13, 2024
Assignee:
Rubedo Life Sciences, Inc.
Inventors:
Paul Keitz, Gus Bergnes, Mark A. Gallop, Marco Quarta
Abstract: Provided herein are senolytic agents for selectively killing senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies and diseases. As disclosed herein, senescent cell-associated diseases and disorders may be treated or prevented by administering at least one senolytic agent or pharmaceutical compositions thereof. The senescent cell-associated diseases or disorders treated or prevented by the methods described herein include, but are not limited to, cardiovascular diseases or disorders, cardiovascular diseases and disorders associated with arteriosclerosis, such as atherosclerosis, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), osteoarthritis, inflammatory diseases or disorders, autoimmune diseases or disorders, pulmonary diseases or disorders, neurological diseases or disorders, dermatological diseases or disorders, chemotherapeutic side effects, radiotherapy side effects, metastasis and metabolic diseases.
Type:
Grant
Filed:
July 11, 2019
Date of Patent:
June 8, 2021
Assignee:
Rubedo Life Sciences, Inc.
Inventors:
Mark A. Gallop, Julian Klein, Marco Quarta